ASI, headquartered in London, is a leading laboratory providing services including clinical trial bioanalysis, forensic toxicology and therapeutic drug monitoring.
Forensic Access, backed by Limerston Capital, offers a broad range of investigation and analysis services in areas including digital forensics, neurology, ballistics, ecology and pathology. The acquisition of ASI will strengthen Forensic Access’s existing biology and toxicology capabilities.
The team was led by partner Will Axtell and senior associate Dominique Sabatini with support from associate Lindsay Chadwick. The wider team included support from Edmund Forey (IP and commercial), Hannah Grayson (employment), Leonie Langley (tax), Clare Coley (pensions) and Lauren Bray (property).
ASI’s managing director Stewart Hollington said: “By joining the Forensic Access group we have taken another step towards providing a full service offering for forensic casework investigation. It was a pleasure working with Penningtons Manches Cooper and we appreciated their calming reassurance at the right time that allowed us to sell ASI with confidence.”